Inovio, VGX Plan Merger For Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
Electroporation-focused Inovio finds an “amazing” fit, CEO says.
You may also be interested in...
Inovio Halts Head And Neck Cancer Trial On Safety Concerns
Firm prematurely stopped a pivotal oncology study investigating its tumor ablation technology after an independent data monitoring committee raised concerns about adverse events.
Roche And Transgene Partner On Therapeutic Vaccine For HPV-Related Diseases
Deal has “potential to expand and evolve into an integrated personalized medicine approach” to HPV-mediated diseases, Roche tells “The Pink Sheet” DAILY.
Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.